{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:27:53Z","timestamp":1795026473768,"version":"4.10.2"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Guselkumab, a fully\u00a0human monoclonal antibody targeting the interleukin (IL)-23p19 subunit, is approved to treat adults with active psoriatic arthritis (PsA). In the Phase 3 DISCOVER-2 trial of 739 bilogico-na\u00efve patients with active PsA, guselkumab 100 mg resulted in less radiographic progression, assessed via change from baseline in PsA-modified van der Heijde-Sharp (vdH-S) score, compared with placebo at week (W) 24 when given at W0, W4, and then every 4 weeks (Q4W) or Q8W. The least squares mean differences from placebo were -0.66 for guselkumab Q4W (<jats:italic>p<\/jats:italic>=0.011) and -0.43\u00a0for guselkumab Q8W (<jats:italic>p<\/jats:italic>=0.072). Reports suggest baseline C-reactive protein (CRP) and joint erosions are strongly prognostic of poor outcomes, especially radiographic progression, in PsA patients. We designed a trial (APEX) to further assess the effect of guselkumab on radiographic progression in patients with active\u00a0PsA\u00a0and risk factors for radiographic progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients are eligible\u00a0for APEX if they have had PsA for \u22656 months and active disease (\u22653 swollen and \u22653 tender joints, CRP \u22650.3 mg\/dL) despite prior therapy with conventional synthetic disease-modifying antirheumatic drugs, apremilast, and\/or nonsteroidal anti-inflammatory drugs, with \u22652 joints with erosions on baseline radiographs (hands and feet). The primary and major secondary endpoints are the proportion of patients achieving \u226520% improvement in American College of Rheumatology response criteria (ACR20) response at W24 and change from baseline at W24 in PsA-modified vdH-S score, respectively. Sample sizes of 350\/250\/350 for guselkumab Q8W\/guselkumab Q4W\/placebo are expected to provide &gt;99% power to detect significant differences in W24 ACR20 response rates for each guselkumab group vs placebo, as well as \u226590% (Q4W vs placebo) and \u226580% (Q8W vs placebo) power to detect a significant difference in PsA-modified vdH-S score change at W24. A Cochran-Mantel-Haenszel test and analysis of covariance will compare treatment efficacy for the primary and major secondary endpoints, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>DISCOVER-2 findings informed the design of APEX, a Phase 3b study intended to further evaluate the impact of guselkumab in patients with active PsA and known risk factors for radiographic progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was registered at ClinicalTrials.gov, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04882098\">NCT04882098<\/jats:ext-link>. Registered on 11 May 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06945-y","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T08:03:17Z","timestamp":1673337797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa P.","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Proton","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"7","key":"6945_CR1","first-page":"1434","volume":"35","author":"CT Ritchlin","year":"2008","unstructured":"Ritchlin CT. From skin to bone: translational perspectives on psoriatic disease. J Rheumatol. 2008;35(7):1434\u20137.","journal-title":"J Rheumatol"},{"issue":"6","key":"6945_CR2","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N","volume":"41","author":"DD Gladman","year":"1998","unstructured":"Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum. 1998;41(6):1103\u201310.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"6945_CR3","first-page":"1842","volume":"28","author":"KB Sokoll","year":"2001","unstructured":"Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28(8):1842\u20136.","journal-title":"J Rheumatol"},{"issue":"4","key":"6945_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","volume":"30","author":"JC Torre Alonso","year":"1991","unstructured":"Torre Alonso JC, Rodr\u00edguez P\u00e9rez A, Arribas Castrillo JM, Ballina Garc\u00eda J, Riestra Noriega JL, L\u00f3pez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol. 1991;30(4):245\u201350.","journal-title":"Br J Rheumatol"},{"issue":"10","key":"6945_CR5","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40(10):1868\u201372.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6945_CR6","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","volume":"76","author":"A Kerschbaumer","year":"2017","unstructured":"Kerschbaumer A, Baker D, Smolen JS, Aletaha D. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76(12):2038\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6945_CR7","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74(6):1045\u201350.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6945_CR8","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003;42(12):1460\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"10230","key":"6945_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke W-H, Kollmeier AP, Hsia EC, Subramanian RA, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"10230","key":"6945_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"issue":"9894","key":"6945_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382(9894):780\u20139.","journal-title":"Lancet"},{"issue":"6","key":"6945_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"C Ritchlin","year":"2014","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, et al. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis. 2014;73(6):990\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6945_CR13","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60(4):976\u201386.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6945_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13075-020-2103-8","volume":"22","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gladman DD, Kavanaugh A, Mease PJ. Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. Arthritis Res Ther. 2020;22(1):18.","journal-title":"Arthritis Res Ther"},{"issue":"9861","key":"6945_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0140-6736(12)62160-6","volume":"381","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Dickersin K, Moher D. SPIRIT 2013: new guidance for content of clinical trial protocols. Lancet. 2013;381(9861):91\u20132.","journal-title":"Lancet"},{"key":"6945_CR16","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Gotzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ"},{"issue":"2","key":"6945_CR17","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137\u201345.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6945_CR18","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727\u201335.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6945_CR19","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator\u2019s Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"6945_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157(4):238\u201344.","journal-title":"Dermatologica"},{"issue":"Suppl 2","key":"6945_CR21","first-page":"ii61","volume":"64","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64(Suppl 2):ii61\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6945_CR22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/art.1780350105","volume":"35","author":"DM van der Heijde","year":"1992","unstructured":"van der Heijde DM, van Leeuwen MA, van Riel PL, Koster AM, van\u2019t Hof MA, van Rijswijk MH, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum. 1992;35(1):26\u201334.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6945_CR23","doi-asserted-by":"publisher","first-page":"887","DOI":"10.4088\/JCP.13m08398","volume":"74","author":"JC Mundt","year":"2013","unstructured":"Mundt JC, Greist JH, Jefferson JW, Federico M, Mann JJ, Posner K. Prediction of suicidal behavior in clinical research by lifetime suicidal ideation and behavior ascertained by the electronic Columbia-Suicide Severity Rating Scale. J Clin Psychiatry. 2013;74(9):887\u201393.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"6945_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168(12):1266\u201377.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"6945_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","volume":"81","author":"LC Coates","year":"2022","unstructured":"Coates LC, Gossec L, Theander E, Bergmans P, Neuhold M, Karyekar CS, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). Ann Rheum Dis. 2022;81(3):359\u201369.","journal-title":"Ann Rheum Dis"},{"key":"6945_CR26","volume-title":"Combining analysis results from multiply imputed categorical data","author":"B Ratitch","year":"2013","unstructured":"Ratitch B, Lipkovich I, O\u2019Kelly M. Combining analysis results from multiply imputed categorical data: PharmaSUG; 2013."},{"issue":"8","key":"6945_CR27","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"6945_CR28","doi-asserted-by":"publisher","first-page":"e000606","DOI":"10.1136\/rmdopen-2017-000606","volume":"4","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Gladman DD, Samad AS, Coates LC, Liu LXH, Aras GA, et al. Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). RMD Open. 2018;4(1):e000606.","journal-title":"RMD Open"},{"issue":"6","key":"6945_CR29","first-page":"890","volume":"77","author":"P Mease","year":"2018","unstructured":"Mease P, van der Heijde D, Landew\u00e9 R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77(6):890\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6945_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6945_CR31","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1136\/annrheumdis-2012-202959","volume":"73","author":"L Eder","year":"2014","unstructured":"Eder L, Thavaneswaran A, Chandran V, Gladman DD. Tumour necrosis factor alpha blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. Ann Rheum Dis. 2014;73(6):1007\u201311.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6945_CR32","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/art.40851","volume":"71","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 2019;71(7):1112\u201324.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"6945_CR33","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00296-019-04345-1","volume":"39","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Accortt NA, Rebello S, Etzel CJ, Harrison RW, Aras GA, et al. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting. Rheumatol Int. 2019;39(9):1547\u201358.","journal-title":"Rheumatol Int"},{"issue":"4","key":"6945_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Chakravarty SD, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73(4):604\u201316.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"6945_CR35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, Hsia EC, Kollmeier AP, Xu XL, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06945-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06945-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T08:06:11Z","timestamp":1673337971000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06945-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6945"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06945-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,10]]},"assertion":[{"value":"21 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is being conducted in compliance with the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. The protocol will be approved by each site\u2019s governing ethical body. Each study patient is required to have provided written informed consent prior to the conduct on any study-related procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CTR: Grant\/research support from AbbVie, Amgen, and UCB; consulting fees from Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB; LCC: funded by a National Institute for Health Research Clinician Scientist award. The research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We acknowledge the support of the National Institute for Health Research Clinical Research Network (NIHR CRN); PJM: Grant\/research support from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; consulting fees from AbbVie, Aclaris, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Inmagene, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Sun Pharma, and UCB; DvH: Consulting fees from AbbVie, Bayer, Bristol Myers Squibb, Cyxone, Eisai, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer, and UCB; serves as the director of Imaging Rheumatology BV; JS, APK: Employees of Janssen Research & Development, LLC; own stock or stock options in Johnson & Johnson, of which Janssen Research & Development, LLC is a wholly owned subsidiary; YJ: Employee of Cytel,\u00a0contracted to provide services to Janssen Research & Development, LLC; MS: Employee of Janssen Pharmaceutical Companies of Johnson & Johnson; owns stock or stock options in Johnson & Johnson; PR: Grant\/research support from Janssen and Novartis; consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}